TScan Therapeutics, Inc. (NASDAQ:TCRX) was reported as a holding by 52 institutional investors in 13F filings for the quarter ended September 30, 2026.
Collectively, these holders controlled 25.18% of TScan Therapeutics' outstanding shares in Q3 2026, down from 27.42% in Q2 2026.
Total shares held in TScan Therapeutics fell 8.12% versus Q2 2026, while the number of holders fell 27.78% versus Q3 2025.
Looking at the 52 holders of TCRX individually, 15 added to their positions, 21 reduced their stakes and 16 left their positions unchanged.
In total, institutional investors held 32.74Mn shares of TScan Therapeutics at the end of Q3 2026, down 2.89Mn from the prior quarter and down 1.84Mn from a year earlier.
Lynx1 Capital Management LP led 13F holders of TCRX with 8.02Mn shares as of September 30, 2026, or 6.17% of shares outstanding.
Among existing holders, the largest additions to TScan Therapeutics in Q3 2026 came from Boothbay Fund Management, LLC (+2.63Mn shares), Acadian Asset Management LLC (+386.63K shares), Vanguard Capital Management LLC (+350.06K shares), UBS Group AG (+39.37K shares) and Geode Capital Management, LLC (+19.52K shares).
Among holders that kept a stake in TScan Therapeutics, the biggest sellers in Q3 2026 were Citadel Advisors LLC (-957.35K shares), Marshall Wace, LLP (-417.75K shares), BlackRock, Inc. (-396.79K shares), Two Sigma Investments, LP (-305.36K shares) and Jane Street Group, LLC (-151.31K shares).
According to Business Quant data, the leading holders of TCRX for Q3 2026 were Lynx1 Capital Management LP (8.02Mn shares), BVF Inc (5.56Mn shares), Boothbay Fund Management, LLC (3.4Mn shares), Baker Bros. Advisors LP (2.78Mn shares), Vanguard Capital Management LLC (2.51Mn shares), Acadian Asset Management LLC (1.69Mn shares), Two Sigma Investments, LP (1.64Mn shares), Deer Management Co. LLC (1.25Mn shares), Renaissance Technologies LLC (1.21Mn shares) and DC Funds, LP (630K shares).